Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia

Chronic Diseases and Injuries in Canada

Volumn 34, Issue 2-3, 2014, Pages 145-153

  Marrie, Ruth Ann ^a   Fisk, J D ^b,c   Stadnyk, K J ^c   Tremlett, Helen ^d   Wolfson, Christina ^e,f   Warren, Sharon ^g   Bhan, Virender ^b,c   Yu, Bo Nancy ^a   Leung, Stella ^a   Elliott, Lawrence ^a   Caetano, Patricia ^a   Blanchard, James F ^a   Svenson, Lawrence W ^a   Profetto McGrath, Joanne ^g   Jette, Nathalie ^h   Patten, Scott B ^h   Evans, Charity ⁱ   Ploughman, Michelle ^j  

^a UNIVERSITY OF MANITOBA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Capital District Health Authority   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ UNIVERSITY OF SASKATCHEWAN   (Canada)

^j MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

more..

Author keywords

Administrative data; Comorbidity; Multiple sclerosis; Validation

Indexed keywords

ADULT; ANXIETY; CANADA; COMORBIDITY; COMPARATIVE STUDY; DEPRESSION; DIABETES MELLITUS; EPILEPSY; FACTUAL DATABASE; FEMALE; HEART DISEASES; HUMAN; HYPERLIPIDEMIAS; HYPERTENSION; INFLAMMATORY BOWEL DISEASES; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SELF REPORT; VALIDATION STUDY;

ADULT; ANXIETY; COMORBIDITY; DATABASES, FACTUAL; DEPRESSION; DIABETES MELLITUS; EPILEPSY; FEMALE; HEART DISEASES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INFLAMMATORY BOWEL DISEASES; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MANITOBA; MIDDLE AGED; MULTIPLE SCLEROSIS; NOVA SCOTIA; SELF REPORT;

EID: 84903996814     PISSN: 02288699     EISSN: 14818523     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA. Causes and consequences of comor-bidity: a review. J Clin Epidemiol. 2001; 54(7):661-74.
2. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology. 2007; 69(19):1850-8.
3. Dean G. How many people in the world have multiple sclerosis? Neuroepidemiology. 1994;13(1-2):1-7.
4. Evans C, Beland S, Kulaga S, et al. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepide-miology. 2013;40(3):195-210.
5. Warren SA, Svenson LW, Warren KG. Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada. Mult Scler. 2008;14(7):872-9.
6. Beck CA, Metz LM, Svenson LW, Patten SB. Regional variation of multiple sclerosis prevalence in Canada. Mult Scler. 2005; 11(5):516-9.
7. Marrie RA, Cutter G, Tyry T. Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis. Mult Scler. 2011;17(12):1464-71.
8. Marrie RA, Horwitz RI, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009;72(2): 117-24.
9. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74(13):1041-7.
10. Warren SA, Turpin KV, Pohar SL, Jones CA, Warren KG. Comorbidity and health-related quality of life in people with multiple sclerosis. Int J MS Care. 2009;11(1):6-16.
11. Marrie RA, Horwitz RI. Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol. 2010;9(8):820-8.
12. The burden of neurological diseases, disorders and injuries in Canada. Ottawa (ON): Canadian Institute for Health Information: 2007.
13. Lash TL, Mor V, Wieland D, Ferrucci L, Satariano W, Silliman RA. Methodology, design, and analytic techniques to address measurement of comorbid disease. J Gerontol A Biol Sci Med Sci. 2007;62(3): 281-5.
14. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol. 2004;57(10):1096-103.
15. Patten S. Integrating data from clinical and administrative databases in pharmacoepi-demiological research. Can J Clin Pharmacol. 1998;5(2):92-7.
16. National Diabetes Surveillance System. Responding to the challenge of diabetes in Canada - First Report of the National Diabetes Surveillance System (NDSS) 2003 [Internet]. Ottawa (ON): Health Canada; 2003 [cited 2006 Jan 10]. Available at: http://publications.gc.ca/collections/Collection/H39-4-21-2003E.pdf
17. Marrie R, Yu B, Leung S, et al. Rising prevalence of vascular comorbidities in MS: validation of administrative definitions for diabetes, hypertension, hyperlipidemia. Mult Scler. 2012;18(9):1310-9.
18. Marrie RA, Fisk JD, Yu BN, et al. Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol. 2013;13(1):16.
19. Marrie RA, Yu BN, Leung S, et al. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology. 2012;40(2): 85-92.
20. Marrie RA, Yu BN, Leung S, et al. The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data. Neuroepide-miology. 2012;39(2):135-42.
21. Lix LM, Walker R, Quan H, Nesdole R, Yang J, Chen G. Features of physician services databases in Canada. Chronic Dis Inj Can. 2012;32(4):186-93.
22. Health Information Management Branch. Population report. Winnipeg (MB): Manitoba Health and Healthy Living; 2008 June 1.
23. Marrie RA, Yu BN, Leung S, et al. The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: a population-based study. Mult Scler Rel Dis. 2012;1(4):162-7.
24. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status, and multiple sclerosis. Mult Scler. 2008;14(8):1091-8.
25. Lix L, Yogendran M, Shaw S, Burchill C, Metge C, Bond R. Population-based data sources for chronic disease surveillance. Chronic Dis Can. 2008;29(1):22-30.
26. Marrie RA, Yu N, Blanchard JF, Leung S, Elliott L. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology. 2010;74(6):465-71.
27. Horton M, Rudick RA, Hara-Cleaver C, Marrie RA. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology. 2010;35(2): 83-90.
28. Marrie RA, Yu BN, Leung S, et al. Prevalence and incidence of ischemic heart disease in multiple sclerosis: a population-based validation study. Mult Scler Rel Dis. 2013;2(4):355-61.
29. Quach S, Blais C, Quan H. Administrative data have high variation in validity for recording heart failure. Can J Cardiol. 2010;26(8):306-12.
30. Population, urban and rural, by province and territory (Nova Scotia) [Internet]. Ottawa (ON): Statistics Canada; 2011. Available at: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo62d-eng.htm
31. Marrie R, Fisk J, Stadnyk K, et al. The incidence and prevalence of multiple sclerosis in Nova Scotia, Canada. Can J Neurol Sci. 2013;40(6):824-31.
32. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian Province: a population-based study. Amer J Epidemiol. 1999;149(10):916-24.
33. Lowe AM, Roy P-O, B-Poulin M, et al. Epidemiology of Crohn's Disease in Quebec, Canada. Inflamm Bowel Dis. 2009;15(3): 429-35.
34. Veuglers PJ, Fisk JD, Brown MG, et al. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. Mult Scler. 2009;15:1286-94.
35. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002;40(8 Suppl): IV-26-35.
36. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.
37. Kisely S, Lin E, Gilbert C, Smith M, Campbell LA, Vasiliadis HM. Use of administrative data for the surveillance of mood and anxiety disorders. Aust N Z J Psychiatry. 2009;43(12):1118-25.
38. Martens P, Fransoo R, McKeen N, et al. Patterns of regional mental illness disorder diagnoses and service use in Manitoba: a population-based study [Internet]. Winnipeg (MB): Manitoba Centre for Health Policy; 2004 Sep [revised 2004 Nov 18; cited 2013 Jan 24]. Available at: http://mchp-appserv.cpe.umanitoba.ca/reference/mental.health.pdf
39. West SL, Richter A, Melfi CA, McNutt M, Nennstiel ME, Mauskopf JA. Assessing the Saskatchewan database for outcomes research studies of depression and its treatment. J Clin Epidemiol. 2000;53(8): 823-31.
40. Tu K, Campbell NRC, Chen Z, Cauch-Dudek KJ, McAlister FA. Accuracy of administrative databases in identifying patients with hypertension. Open Medicine. 2007;1(1): e18-26.
41. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3): 512-6.
42. Reid AY, St Germaine-Smith C, Liu M, et al. Development and validation of a case definition for epilepsy for use with administrative health data. Epilepsy Res. 2012; 102(3):173-9.
43. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1): 8-27.
44. Wilchesky M, Tamblyn RM, Huang A. Validation of diagnostic codes within medical services claims. J Clin Epidemiol. 2004; 57(2):131-41.
45. Luthi JC, Troillet N, Eisenring MC, et al. Administrative data outperformed single-day chart review for comorbidity measure. Int J Qual Health Care. 2007;19(4):225-31.
46. Bayliss EA, Ellis JL, Steiner JF. Subjective assessments of comorbidity correlate with quality of life health outcomes: initial validation of a comorbidity assessment instrument. Health and Quality of Life Outcomes. 2005;3:51.